WO2007080324A3 - Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. - Google Patents

Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. Download PDF

Info

Publication number
WO2007080324A3
WO2007080324A3 PCT/FR2007/000050 FR2007000050W WO2007080324A3 WO 2007080324 A3 WO2007080324 A3 WO 2007080324A3 FR 2007000050 W FR2007000050 W FR 2007000050W WO 2007080324 A3 WO2007080324 A3 WO 2007080324A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic use
derivatives
preparation
pyridopyrimidone
general formula
Prior art date
Application number
PCT/FR2007/000050
Other languages
English (en)
Other versions
WO2007080324A2 (fr
Inventor
Pierre Perreaut
Samir Jegham
Bernard Bourrie
Pierre Casellas
Jean-Robert Labrosse
Florence Durand
Original Assignee
Sanofis Aventis
Pierre Perreaut
Samir Jegham
Bernard Bourrie
Pierre Casellas
Jean-Robert Labrosse
Florence Durand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofis Aventis, Pierre Perreaut, Samir Jegham, Bernard Bourrie, Pierre Casellas, Jean-Robert Labrosse, Florence Durand filed Critical Sanofis Aventis
Priority to EP07717935A priority Critical patent/EP1979352A2/fr
Priority to JP2008549907A priority patent/JP2009523159A/ja
Publication of WO2007080324A2 publication Critical patent/WO2007080324A2/fr
Publication of WO2007080324A3 publication Critical patent/WO2007080324A3/fr
Priority to US12/166,431 priority patent/US7842806B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

L'invention à pour objet des dérivés de pyrido[2,3-d]pyrimidone, leur préparation et leur application en thérapeutique, de formule générale (I) qui suit : (I) à l'état de base ou de sel d'addition à un acide pharmaceutiquement acceptable, à l'état d'hydrates ou de solvates, ainsi que sous forme d'énantiomères, de diastéréoisomères et leur mélange. L'invention a également pour objet leur procédé de préparation, des compositions pharmaceutiques contenant un composé de formule générale (I), et leur utilisation en thérapeutique.
PCT/FR2007/000050 2006-01-13 2007-01-12 Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. WO2007080324A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07717935A EP1979352A2 (fr) 2006-01-13 2007-01-12 Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
JP2008549907A JP2009523159A (ja) 2006-01-13 2007-01-12 ピリドピリミドン誘導体、これらの調製、これらの治療上の使用
US12/166,431 US7842806B2 (en) 2006-01-13 2008-07-02 Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600298 2006-01-13
FR0600298A FR2896246B1 (fr) 2006-01-13 2006-01-13 Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/166,431 Continuation US7842806B2 (en) 2006-01-13 2008-07-02 Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof

Publications (2)

Publication Number Publication Date
WO2007080324A2 WO2007080324A2 (fr) 2007-07-19
WO2007080324A3 true WO2007080324A3 (fr) 2007-08-30

Family

ID=36678623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/000050 WO2007080324A2 (fr) 2006-01-13 2007-01-12 Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Country Status (5)

Country Link
US (1) US7842806B2 (fr)
EP (1) EP1979352A2 (fr)
JP (1) JP2009523159A (fr)
FR (1) FR2896246B1 (fr)
WO (1) WO2007080324A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2015019037A1 (fr) * 2013-08-05 2015-02-12 Almac Discovery Limited Composés pharmaceutiques
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
PL3191099T3 (pl) * 2014-09-12 2019-07-31 Biolab Sanus Farmacéutica Ltda Pochodne pirydopirymidyn

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034867A1 (fr) * 1995-05-03 1996-11-07 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINES DESTINEES A INHIBER LA PROLIFERATION CELLULAIRE INDUITE PAR LES TYROSINES KINASES
WO2002012238A2 (fr) * 2000-08-04 2002-02-14 Warner-Lambert Company 2-(4-pyridyl)amino-6-dialcoxyphenyl-pyrido[2,3-d]pyrimidine-7-ones
WO2004063195A1 (fr) * 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Inhibiteurs de kinases a base de pyridopyrimidine
WO2005105097A2 (fr) * 2004-04-28 2005-11-10 Gpc Biotech Ag Derives de pyridopyrimidine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
MX9702245A (es) 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
AR030044A1 (es) 2000-01-25 2003-08-13 Warner Lambert Co Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas
EE200200506A (et) 2000-03-06 2004-02-16 Warner-Lambert Company 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
WO2003000011A2 (fr) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Nouvelles pyridopyrimidines et leur utilisation
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
PE20060569A1 (es) 2004-07-16 2006-06-22 Boehringer Ingelheim Int Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034867A1 (fr) * 1995-05-03 1996-11-07 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINES DESTINEES A INHIBER LA PROLIFERATION CELLULAIRE INDUITE PAR LES TYROSINES KINASES
WO2002012238A2 (fr) * 2000-08-04 2002-02-14 Warner-Lambert Company 2-(4-pyridyl)amino-6-dialcoxyphenyl-pyrido[2,3-d]pyrimidine-7-ones
WO2004063195A1 (fr) * 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Inhibiteurs de kinases a base de pyridopyrimidine
WO2005105097A2 (fr) * 2004-04-28 2005-11-10 Gpc Biotech Ag Derives de pyridopyrimidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PALMER B D ET AL: "Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]p yrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 15, no. 7, 1 April 2005 (2005-04-01), pages 1931 - 1935, XP004789411, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2007080324A2 (fr) 2007-07-19
FR2896246A1 (fr) 2007-07-20
JP2009523159A (ja) 2009-06-18
EP1979352A2 (fr) 2008-10-15
US7842806B2 (en) 2010-11-30
FR2896246B1 (fr) 2008-08-15
US20090048277A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2006016067A3 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer
WO2006042954A8 (fr) Dérivés de 2-amido-4-phenylthiazole, leur préparation et leur application en thérapeutique
WO2008002244A3 (fr) Nouveaux composés 384
WO2007040438A3 (fr) Derives d'imidazo(4,5-b) pyridine utilises comme inhibiteurs de la glycogene synthase kinase 3 pour le traitement de la demence et de troubles neurodegeneratifs
WO2008002245A8 (fr) Nouveaux composés 385
WO2006077025A3 (fr) Morpholines en tant qu'agonistes de 5ht2c
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
TW200626553A (en) Novel compounds
WO2006011050A3 (fr) Derives de pyridine
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
ZA200707901B (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
HK1135964A1 (en) Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics
WO2007080324A3 (fr) Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
UA99447C2 (ru) Способ получения силденафила
WO2009140341A3 (fr) Compositions d'atorvastatine
WO2008006795A3 (fr) Composés d'indole
PL1730144T3 (pl) Podstawione pochodne 1,4,8-triazaspiro[4.5]dekan-2-onu
PL1869038T3 (pl) Podstawione pochodne 5,6,7,8-tetrahydro-imidazo[1,2-a]pirydyn-2-yloaminy i ich zastosowanie do wytwarzania środków leczniczych
WO2011009714A3 (fr) Dérivés de sel de benzoquinolizinium comme agents anti-cancéreux
WO2006072000A3 (fr) Compositions pharmaceutiques a base de derives d'acide xanthurenique et methodes associees
WO2004083185A3 (fr) Composes imidazole
WO2006074919A3 (fr) Amides d'acide 3-amino-6-aryl-thieno[2,3-b]pyridine-2-carboxylique, preparations pharmaceutiques contenant ces composes et utilisation desdits composes comme inhibiteurs de la liberation de tnf$g(a)
WO2008039894A3 (fr) Compositions pharmaceutiques d'atorvastatine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007717935

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008549907

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE